Get startedLog in
    Picture of Castle Biosciences logo

    CSTL — Castle Biosciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapHigh Flyer
    All News

    Brief: Castle Biosciences enters collaboration, license agreement with Scibase to develop diagnostic tests for dermatologic diseases

    Picture of Castle Biosciences logoCastle Biosciences
    16/06/2025 21:55
    June 16 (Reuters) - Castle Biosciences Inc CSTL.O:

CASTLE BIOSCIENCES ENTERS COLLABORATION AND LICENSE AGREEMENT WITH SCIBASE TO DEVELOP DIAGNOSTIC TESTS FOR DERMATOLOGIC DISEASES

CASTLE BIOSCIENCES INC - SCIBASE TO RECEIVE SINGLE-DIGIT ROYALTY AND DOUBLE-DIGIT MARK-UP ON SALES

CASTLE BIOSCIENCES INC - SCIBASE TO RECEIVE $5 MILLION MILESTONE PAYMENT WHEN CASTLE SALES REACH $50 MILLION ANNUALLY

CASTLE BIOSCIENCES INC - SCIBASE TO DEFER CLINICAL DEVELOPMENT COSTS FOR INITIAL INDICATION

Source text: ID:nGNX3mnwWC

Further company coverage: CSTL.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Castle Biosciences

    See all news